is the conduit for low oxygen tension-induced ATP release from human erythrocytes. Am J Physiol Heart Circ Physiol 299: H1146 -H1152, 2010. First published July 9, 2010; doi:10.1152/ajpheart.00301.2010.-Erythrocytes release ATP in response to exposure to the physiological stimulus of lowered oxygen (O 2) tension as well as pharmacological activation of the prostacyclin receptor (IPR). ATP release in response to these stimuli requires activation of adenylyl cyclase, accumulation of cAMP, and activation of protein kinase A. The mechanism by which ATP, a highly charged anion, exits the erythrocyte in response to lowered O 2 tension or receptor-mediated IPR activation by iloprost is unknown. It was demonstrated previously that inhibiting pannexin 1 with carbenoxolone inhibits hypotonically induced ATP release from human erythrocytes. Here we demonstrate that three structurally dissimilar compounds known to inhibit pannexin 1 prevent ATP release in response to lowered O 2 tension but not to iloprost-induced ATP release. These results suggest that pannexin 1 is the conduit for ATP release from erythrocytes in response to lowered O 2 tension. However, the identity of the conduit for iloprost-induced ATP release remains unknown.
erythrocytes in response to mechanical deformation (25, 45) , was once considered to be a possible ATP conduit in cells. However, more recent studies demonstrate that CFTR is not likely to serve as an ATP conduit itself but rather regulates other channels that serve that role (1, 7, 19, 24, 51) .
Recently, the protein family of pannexins, orthologs of the invertebrate innexins, has been implicated as ATP conduits in many cell types including astrocytes (23) , airway epithelial cells (36) , and erythrocytes (28) . Locovei et al. (28) demonstrated that pannexin 1 is present in erythrocytes and that ATP release in response to hypotonic stress can by inhibited by the pannexin 1 inhibitor carbenoxolone. In addition, that group was able to detect erythrocyte pannexin 1-like channel activity when the erythrocyte was depolarized (28) . Here we extend the former observation and show that treating erythrocytes with three pannexin 1 inhibitors prevents low O 2 tension-induced ATP release. In contrast, these inhibitors had no effect on ATP release in response to receptor-mediated activation of the prostacyclin receptor (IPR) with Ilo. In addition, we demonstrate that, similar to mechanical deformation-induced ATP release, CFTR is required for low O 2 tension-and Ilo-induced ATP release. These results demonstrate that although CFTR is required for both low O 2 tension-and Ilo-induced ATP release, the final conduits responsible for that ATP release are different.
METHODS

Isolation of healthy human erythrocytes.
Human blood was collected from 12 men and 17 women (average age 34.7 Ϯ 2.3 yr; range 23-60 yr) by venipuncture with a syringe containing heparin (500 U) and centrifuged at 500 g and 4°C for 10 min. The plasma, buffy coat, and uppermost erythrocytes were removed by aspiration and discarded. The remaining erythrocytes were washed three times in buffer containing (in mM) 21 .0 tris(hydroxymethyl)aminomethane, 4.7 KCl, 2.0 CaCl 2, 140.5 NaCl, 1.2 MgSO4, and 5.5 glucose, with 0.5% bovine albumin fraction V, final pH 7.4. Erythrocytes isolated in this fashion contain Ͻ1 leukocyte per 50 high-power fields (ϳ8 -10 leukocytes/mm 3 ) and are devoid of platelets (21) . Cells were prepared on the day of use.
Determination of ATP release from erythrocytes in response to exposure to reduced O 2 tension. Washed erythrocytes were diluted to a 20% hematocrit in a buffer containing bicarbonate (in mM: 4.7 KCl, 2.0 CaCl 2, 140.5 NaCl, 1.2 MgSO4, 11 glucose, 23.8 NaHCO3, with 0.2% dextrose and 0.5% BSA, pH 7.4) at 37°C. Erythrocytes were equilibrated for 30 min in a thin-film blood tonometer (Dual Equilibrator model DEQ1, Cameron Instrument) (9) with a gas mixture containing 15% O 2, 6% CO2, balance N2 (normoxia, PO2 ϭ 110.8 Ϯ 1.7 mmHg). The erythrocytes were then exposed sequentially to gases with compositions of 4.5% O 2, 6% CO2, balance N2 and 0% O2, 6% CO 2, balance N2. pH, PO2, and PCO2 were determined after a 10-min exposure to each gas mixture with a blood gas analyzer (model pHOx, Nova Biomedical). Exposure of erythrocytes sequentially to gases with compositions of 4.5% O 2, 6% CO2, balance N2 and 0% O2, 6% CO2, balance N2 for 10 min each resulted in PO2 of the erythrocyte suspension of 34.1 Ϯ 0.59 and 12.3 Ϯ 1.0 mmHg, respectively. The amount of ATP released from erythrocytes was determined during normoxia and after the 10-min exposure to each gas mixture.
Determination of ATP release from erythrocytes in response to exposure to reduced O 2 tension in absence and presence of a CFTR inhibitor. Experiments in which erythrocytes were exposed to lowered O 2 tension, identical to those described above, were performed in the presence or absence of glibenclamide (10 M, Sigma) or its vehicle [N,N-dimethylformamide (DMF)] for 30 min. Inhibition of ATP release from erythrocytes was studied with the 0% O 2, 6% CO2, balance N 2 gas composition because that was the concentration at which maximal low O 2-induced ATP release occurred. The concentration of glibenclamide was chosen on the basis of previous studies (45) .
Determination of ATP release from erythrocytes in response to exposure to iloprost in absence and presence of CFTR inhibitor. Isolated erythrocytes, exposed to room air and temperature, were diluted to a hematocrit of 20% in a buffer containing (in mM) 21 (28, 34, 42) .
Incubation of erythrocytes with iloprost (1 M) in absence and presence of pannexin 1 inhibitors. Experiments in which erythrocytes were exposed to Ilo, identical to those described above, were performed with erythrocytes that were preincubated with carbenoxolone (100 M), probenecid (100 M), 10 panx1 peptide (200 M), or their vehicles (DMF or PBS). Erythrocytes were then incubated with Ilo (1 M), and ATP release was measured after 5, 10, and 15 min. The maximal response to Ilo is reported.
Measurement of ATP. ATP was measured with the luciferinluciferase assay as described previously (45, 49) . A 200-l sample of erythrocyte suspension (0.04% hematocrit) was injected into a cuvette containing 100 l of firefly lantern extract (10 mg/ml; Sigma) and 100 l of a solution of synthetic D-luciferin (50 mg/100 ml; RPI). The light emitted was detected with a luminometer (Turner Designs). A standard curve for ATP (Calbiochem) was obtained for each experiment. Cell counts were obtained from the suspension of erythrocytes, and amounts of ATP measured were normalized to 4 ϫ 10 8 cells/ml.
Measurement of total intracellular ATP of erythrocytes.
A known number of erythrocytes, determined by counting, were lysed in distilled water. ATP was measured as described above. Values were normalized to ATP concentration per erythrocyte.
Measurement of free hemoglobin. To exclude the possibility that hemolysis contributed to the levels of ATP measured, after ATP determinations samples were centrifuged at 500 g and 4°C for 10 min and the presence of free hemoglobin in the supernatant was determined by light absorption at a wavelength of 405 nm. If any free hemoglobin was detected the studies were not included, to ensure that hemolysis was not influencing the amounts of extracellular ATP measured.
Data analysis. Statistical significance among groups was determined by analysis of variance (ANOVA). In the event that the F ratio indicated that a change had occurred, a Fisher's least significant difference (LSD) test was performed to identify individual differences. Results are reported as means Ϯ SE. In all studies, n refers to the number of different individuals from which erythrocyte samples were obtained. For each set of experiments, no sample from an individual was used twice. However, some individuals were studied in more than one experimental protocol.
Institutional approval. The protocol used to obtain blood from humans was approved by the Institutional Review Board of Saint Louis University.
RESULTS
Effect of exposure of human erythrocytes to low O 2 tension on ATP release.
Exposure of erythrocytes to a gas composed of 15% O 2 , 6% CO 2 , balance N 2 for 30 min resulted in pH, PCO 2, and PO 2 of 7.37 Ϯ 0.01, 35.4 Ϯ 0.7 mmHg, and 110.8 Ϯ 1.7 mmHg, respectively. Subsequent exposure of erythrocytes to a gas containing 4.5% O 2 for 10 min resulted in pH, PCO 2 , and PO 2 of 7.37 Ϯ 0.01, 36.0 Ϯ 0.7 mmHg, and 34.1 Ϯ 0.6 mmHg, respectively. Finally, exposure of erythrocytes to 0% O 2 for 10 min resulted in pH, PCO 2, and PO 2 of 7.38 Ϯ 0.01, 36.3 Ϯ 0.5 mmHg, and 12.3 Ϯ 1.0 mmHg, respectively. The lower the O 2 tension to which erythrocytes were exposed, the greater the amount of ATP released (Fig. 1) .
Effect of glibenclamide (10 M) on low O 2 tension-and iloprost-induced ATP release from human erythrocytes.
Glibenclamide is an irreversible inhibitor of CFTR that prevents ATP release from erythrocytes in response to mechanical deformation (45) . Here we used glibenclamide to determine whether CFTR is a part of the low O 2 tension-or Ilo-induced ATP release pathways. Pretreatment of erythrocytes with glibenclamide (10 M) resulted in a decrease in ATP release in response to exposure to lowered O 2 tension (PO 2 ϭ 17.7 Ϯ 0.8 mmHg) or Ilo (Fig. 2) . Importantly, glibenclamide (10 M) was previously demonstrated to have no effect on intracellular ATP levels (45), so inhibition of ATP release cannot be attributed to decreased ATP synthesis. Because glibenclamide has been demonstrated to also inhibit ATP-sensitive potassium channels, studies were performed to determine whether activation of ATP-sensitive potassium channels would lead to ATP release. Cromakalim (10 M, 30 min; activator of ATP- Fig. 1 . Effect of exposing human erythrocytes to lowered O2 tension on ATP release. Erythrocytes (RBCs) were exposed to gas with a composition of 15% O2, 6% CO2, balance N2 (15/6) in a tonometer. Cells were then exposed sequentially to gases with compositions of 4.5% O2, 6% CO2, balance N2 (4.5/6) and 0% O2, 6% CO2, balance N2 (0/6). ATP was measured 30 min after exposure to 15% O2 and 10 min after exposure to 4.5% O2 and 0% O2 (n ϭ 20). Values are means Ϯ SE; n ϭ no. of different individuals studied. *P Ͻ 0.05, different from 4.5/6 group; †P Ͻ 0.01, different from 15/6 group. (Fig. 3 ). All three inhibitors had no effect on intracellular ATP levels ( 10 panx1 peptide) while exposed to gas with a composition of 15% O2, 6% CO2, balance N2 in a tonometer. Cells were then exposed to a gas with a composition of 0% O2, 6% CO2, balance N2. ATP was measured 30 min after exposure to 15% O2 and 10 min after exposure to 0% O2. Values are means Ϯ SE; n ϭ no. of different individuals studied. †P Ͻ 0.01, different from all other values. ] for 30 min while exposed to gas with a composition of 15% O2, 6% CO2, balance N2 in a tonometer. Cells were then exposed to a gas with a composition of 0% O2, 6% CO2, balance N2. ATP was measured 30 min after exposure to 15% O2 and 10 min after exposure to 0% O2 (n ϭ 7). Values are means Ϯ SE; n ϭ no. of different individuals studied. *P Ͻ 0. the prostacyclin receptor agonist Ilo showed no decrease in ATP release in the presence of any of the three inhibitors of pannexin 1 (Fig. 4) .
DISCUSSION
Regulated release of ATP occurs in many tissues and contributes to complex signaling pathways within organ systems (18, 38, 39) . Erythrocytes have been demonstrated to release ATP in response to physiological and pharmacological stimuli (5, 31, 33, 44) . ATP that is released from the erythrocyte binds to purinergic receptors on the vascular endothelium, which results in the local generation of vasodilators including nitric oxide and prostaglandins (20, 46) .
The signaling pathways by which erythrocytes release ATP are under active investigation. However, the identity of the final conduit(s) for ATP release has been elusive. The recognized mechanisms by which cells can release ATP are through channels or transporters, via vesicular release, or through lysis of the cell. Since lysis of erythrocytes does not occur through a regulated signaling pathway and erythrocytes do not possess the cellular machinery required for the formation of vesicles (52) , erythrocytes must release ATP through channels or transporters. Our laboratory has demonstrated that erythrocytes release ATP in response to physiological stimuli such as mechanical deformation (45) and exposure of erythrocytes to lowered O 2 tension (5, 48). In addition, erythrocytes possess prostacyclin receptors and release ATP in response to incubation with prostacyclin analogs, including Ilo (33, 44) . It has been demonstrated previously that release of ATP in response to low O 2 tension or prostacyclin analogs requires the activation of two distinct heterotrimeric G proteins (30 -33) . Exposing erythrocytes to lowered O 2 tension activates the G protein G i (31, 32) , whereas exposing erythrocytes to Ilo stimulates the prostacyclin receptor, which is coupled to the G protein G s (33, 44) . Activation of either G protein leads to the stimulation of adenylyl cyclase activity and the accumulation of cAMP (43, 44, 47) .
It has also been demonstrated that CFTR is involved in mechanical deformation-induced ATP release from rabbit erythrocytes. Treating erythrocytes with glibenclamide or niflumic acid, known inhibitors of CFTR, decreases ATP release in response to this stimulus (45) . In addition, erythrocytes from patients with cystic fibrosis do not release ATP in response to mechanical deformation (25) . However, the role of CFTR in the pathways for ATP release in response to lowered O 2 tension or prostacyclin analogs has not been previously determined. In the present study, we demonstrate that glibenclamide also inhibits Ilo-and low O 2 tension-induced ATP release, demonstrating that CFTR is a part of the associated ATP release signal transduction pathways. The inhibitory effect of glibenclamide on ATP release was demonstrated to be through its action on CFTR and not due to an effect on ATP-sensitive potassium channels (45) . Although CFTR is clearly involved in these signaling pathways, studies have demonstrated that CFTR is not an ATP conduit itself but rather regulates the release of ATP via another channel (1, 7, 19 Values (in mM) are means Ϯ SE for n subjects. Fig. 4 . Effect of carbenoxolone, probenecid, and 10 panx1 peptide on Iloinduced ATP release from human erythrocytes. ATP release was measured 5, 10, and 15 min after addition of Ilo (1 M) to erythrocytes that were preincubated with carbenoxolone (100 M, n ϭ 6; A), probenecid (100 M, n ϭ 6; B), 10 Other candidates for ATP conduits include other ATPbinding cassette proteins (MDR1) (2), maxi anion channels (27) , connexins (10, 11) , and, more recently, pannexins (4, 22, 36) . Pannexin 1 is classified as a "gap junction protein" because of the sequence homology it shares with innexins (23, 26) . Pannexins form channels with properties that make them attractive candidates for ATP conduits. These channels are voltage sensitive and can be opened by depolarization, mechanical perturbation, or increased concentrations of intracellular calcium (22, 36) . In addition, unlike connexin hemichannels, pannexin channels can be activated at normal physiological extracellular calcium concentrations (12) .
It was demonstrated that carbenoxolone, a glycyrrhizic acid derivative shown to inhibit pannexin 1, decreased ATP release from erythrocytes in response to hypotonic stress (28) . In that same study, the authors demonstrated that when erythrocytes were exposed to lowered O 2 tension increased uptake of the dye carboxyfluorescein occurred in the erythrocytes, suggesting that a channel large enough for ATP to pass had opened. Although no data were presented, it was noted that treating erythrocytes with carbenoxolone decreased the amount of carboxyfluorescein taken up by these cells in response to lowered O 2 tension. Thus these studies demonstrated that in erythrocytes pannexin 1 serves as a conduit for ATP release in response to hypotonic stress and suggested that pannexin 1 could be involved in ATP release in response to the more physiologically relevant stimulus of exposure of these cells to lowered O 2 tension. In the present study, we measured ATP release from human erythrocytes in response to lowered O 2 tension and demonstrated that treating erythrocytes with three chemically dissimilar agents known to inhibit pannexin 1 inhibits ATP release in response to this stimulus (Fig. 3) . In addition, we measured ATP release from human erythrocytes in response to the IPR agonist Ilo. We demonstrate that pannexin 1 inhibitors do not inhibit ATP release in response to this stimulus (Fig. 4) .
Carbenoxolone, probenecid, and 10 panx1 peptide have all been demonstrated to inhibit pannexin 1 in other cell types (28, 34, 42) . In addition to inhibiting pannexin 1, carbenoxolone has also been demonstrated to inhibit other channels, including connexins and volume-rectifying anion channels (VRACs), thought to serve as ATP conduits in nonerythroid cells (6, 8, 54) . In the study by Locovei et al. (28) , the presence of connexin 43 was not detected in erythrocytes. In addition, the channel properties for the opening of connexins [i.e., low extracellular calcium concentration (12, 35) ] makes it highly unlikely that the inhibitory effects of carbenoxolone on ATP release from the erythrocytes are due to inhibition of connexins. Because carbenoxolone can also inhibit VRACs (54), we examined the effects of two other inhibitors of pannexin 1. Probenecid was first shown to be capable of inhibiting pannexin 1 in a study using frog erythrocytes (42) . In addition, probenecid does not inhibit currents formed by connexin 46 or the chimera connexin 32E 1 43 (42) . To date, no studies have demonstrated that probenecid is capable of inhibiting VRACs. The last inhibitor used was 10 panx1 peptide, a mimetic peptide that was shown to inhibit pannexin 1 through a steric block of the channel (13, 53) . Like carbenoxolone, the 10 panx1 peptide has been demonstrated to also block connexins. However, no studies have demonstrated that this peptide is capable of inhibiting VRACs. The ability of all three chemically dissimilar pharmacological agents known to inhibit pannexin 1 to decrease ATP release in response to lowered O 2 tension supports the role of pannexin 1 as an ATP conduit in the erythrocyte activated by this stimulus.
In addition to its role in the erythrocyte, pannexin 1 has been implicated as an ATP conduit in many cell types including astrocytes (23) , airway epithelial cells (36) , and taste buds (22) . In many of these cell types the stimulus for ATP release was exposure of the cell to hypoosmotic stress (mechanical perturbation) or depolarization, both stimuli that are known to be capable of directly activating pannexin currents. The mechanism by which pannexin 1 is activated in the erythrocyte in response to the stimulus of lowered O 2 tension is not known.
Previous studies, coupled with the work presented here, establish that CFTR is a required component of diverse signaling pathways for ATP release from erythrocytes. In light of previous studies demonstrating the importance of anion countertransport in anoxia-induced ATP release from erythrocytes, the role of CFTR in low O 2 tension-induced ATP release could be as a regulator for chloride currents (19) . It was demonstrated by Bergfeld and Forrester (5) that substitution of permeant anions in the buffer surrounding erythrocytes with methanesulfonate, an impermeant anion, resulted in a significant reduction in ATP release in response to the combination of hypoxia and hypercapnia. These results suggest that permeant extracellular anions are necessary for ATP efflux in response to hypoxic conditions. On the basis of their findings, the authors theorized that the extracellular anions are required in order to maintain a charge balance across the membrane. Although no studies have been performed to determine the importance of permeant extracellular anions in Ilo-induced ATP release, the presence of CFTR in that signaling pathway would suggest that entry of extracellular anions is also required for ATP release in response to this stimulus.
In summary, the studies presented here provide a mechanism by which ATP exits erythrocytes exposed to low O 2 tension. We demonstrate that both CFTR and pannexin 1 are integral components of the low O 2 tension-induced ATP release pathway in human erythrocytes. Although CFTR activity is required for Ilo-induced ATP release, the ATP conduit in this pathway remains unknown.
